Poly (ADP-ribose) polymerase (PARP) inhibitors have been approved in malignancies associated with germlineBRCA1orBRCA2pathogenic variants, such as breast, ovarian, prostate, and pancreatic cancer. In malignancies not associated with germlineBRCA1orBRCA2pathogenic variants, the therapeutic relevance of PARP inhibitors is less clear. Non-small-cell lung cancer (NSCLC) is known to demonstrate somatic alterations inBRCA1orBRCA2gene. The current report is on a gentleman with metastatic lung adenocarcinoma with a somaticBRCA2pathogenic variant, who was effectively treated with olaparib. Furthermore, we discuss the existing data for use of PARP inhibitors in NSCLC. This study highlights the utility of next-generation sequencing in identifying gene mutations and demonstrates how such information can be used to select targeted therapies in patients with actionable molecular alterations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.